Mouse IgG2a Isotype Control - Purified In vivo GOLD Functional Grade

Antibody Details

Product Details

Host Species

Mouse

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

Working Concentration

This isotype control antibody should be used at the same concentration as the primary antibody.

RRID

AB_2737531

Applications and Recommended Usage?
Quality Tested by Leinco

FC This isotype control antibody should be used at the same concentration as the primary antibody.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This Mouse IgG2a (Anti-KLH) isotype control antibody has been tested against selected species' cells and tissues to assure minimal cross reactivity. The isotype of this antibody is Mouse IgG2a, κ. This antibody was chosen as an isotype control after screening on a variety of resting, activated, live, and fixed mouse, rat and human tissue

References & Citations

1.) Ikeda Y. et al. (2003) Blood.101(2):621-3. Article Link
2.) Wright, TM et al. (2000) J Immunol.164(12):6138-46.PubMed
3.) Wright, TM et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed
4.) Nishikawa, Takeji et al. (2000) Journal of Investigative Dermatology114(1): 88-94. PubMed
5.) Gubin et al. (2018) Cell. 175:1014–1030 Journal Link

Technical Protocols